Consort Medical gets US thumbs up

Consort Medical said the first product to use its built-in dose counter had been given the go-ahead by the US Food and Drug Administration.

Consort's Integrated Dose Counter (IDC) is being used in Teva's QNASL nasal aerosol, which treats of nasal seasonal allergy symptoms.

The firm had been developing its IDC for several years in response to a patient and compliance need to let patients know if their device contained sufficient drug and to indicate when they need to seek a further prescription.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up

It provides patients with an indication of how many doses are left inside the canister in line with FDA guidance.

"We are very pleased to announce that the FDA has approved the use of our IDC with Teva's QNASL, making this our first commercially marketed integrated dose counter," said chief executive Jon Glenn.